616224-19-2 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
Benzyl 3,4-diaMinobenzoxylate serves as a crucial building block in the synthesis of a wide array of pharmaceutical compounds. Its unique chemical structure allows it to be a versatile component in creating new medications, contributing to the advancement of treatments for various diseases and conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Benzyl 3,4-diaMinobenzoxylate is employed for its potential biological activity. Its structure and properties make it a valuable tool for researchers who are exploring new avenues in drug discovery, potentially leading to the development of innovative therapeutic agents.
Used in Drug Synthesis:
Benzyl 3,4-diaMinobenzoxylate is utilized in the synthesis of pharmaceutical compounds due to its reactivity and compatibility with other chemical entities. This makes it an essential component in the creation of new drugs, enhancing the pharmaceutical industry's ability to produce effective medications.
Used in Biological Activity Studies:
Given its potential biological activity, Benzyl 3,4-diaMinobenzoxylate is also used in studies aimed at understanding its interactions with biological systems. This can lead to insights into its therapeutic potential and mechanisms of action, which are vital for its application in drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 616224-19-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,1,6,2,2 and 4 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 616224-19:
(8*6)+(7*1)+(6*6)+(5*2)+(4*2)+(3*4)+(2*1)+(1*9)=132
132 % 10 = 2
So 616224-19-2 is a valid CAS Registry Number.
616224-19-2Relevant academic research and scientific papers
NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES
-
Page/Page column 147, (2010/06/17)
This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.
PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM
-
Page 439, (2008/06/13)
The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.
